Guggenheim Raises PT After Actavis (ACT) Has 1Q15 EPS Beat

Go back to Guggenheim Raises PT After Actavis (ACT) Has 1Q15 EPS Beat

Actavis (ACT) Tops Q1 EPS by 38c

May 11, 2015 6:32 AM EDT

Actavis (NYSE: ACT) reported Q1 EPS of $4.30, $0.38 better than the analyst estimate of $3.92. Revenue for the quarter came in at $4.23 billion versus the consensus estimate of $4.04 billion.

"Actavis achieved exceptional operational performance while simultaneously focusing on the completion of the Allergan acquisition and accelerating the integration of our combined company to create a Growth Pharma leader," said Brent... More

Trading Radar for 5/11: Ambac (AMBC), Kandi Technologies (KNDI), Actavis (ACT), AES Corp. (AES) Report

May 8, 2015 2:04 PM EDT

The Trading Radar highlights key earnings and economic announcements for the next trading session:

Before Markets Open:
Earnings:

AES Corp. (NYSE: AES) - consensus EPS $0.25
Actavis (NYSE: ACT) - consensus EPS $3.94
Antares Pharma (Nasdaq: ATRS) - consensus loss $0.05
Centerpoint Energy (NYSE: CNP) - consensus EPS $0.33
Chimerix (Nasdaq: CMRX) - consensus loss $0.57
China XD Plastics (Nasdaq: CXDC) - no... More